2025
Risk of Sight-Threatening Diabetic Retinopathy With GLP-1 RA Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide
Barkmeier A, Deng Y, Swarna K, Herrin J, Polley E, Umpierrez G, Galindo R, Ross J, Mickelson M, McCoy R. Risk of Sight-Threatening Diabetic Retinopathy With GLP-1 RA Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide. Ophthalmology Retina 2025 PMID: 40774571, DOI: 10.1016/j.oret.2025.07.019.Peer-Reviewed Original ResearchDiabetic macular edemaProliferative diabetic retinopathyComparison of patientsDiabetic retinopathyGLP-1Type 2 diabetesRisk of sight-threatening diabetic retinopathyTreatment of diabetic macular edemaGLP-1 RA treatmentSight-threatening diabetic retinopathyGlucagon-like peptide-1 receptor agonistsScore-weighted Cox proportional hazards modelGLP-1 RA usePeptide-1 receptor agonistsModerate cardiovascular disease riskAdvanced diabetic retinopathyPropensity score-weighted Cox proportional hazards modelsDiabetic retinopathy complicationsEffect of semaglutideGLP-1 RAsRetrospective observational studyCox proportional hazards modelsModerate cardiovascular riskMedicare fee-for-service planRoutine clinical practicePharmacological blocking of microfibrillar-associated protein 4 reduces retinal neoangiogenesis and vascular leakage
Schlosser A, Pilecki B, Allen C, Benest A, Lynch A, Hua J, Ved N, Blackley Z, Andersen T, Hennig D, Graversen J, Möller S, Skallerup S, Ormhøj M, Lange C, Agostini H, Grauslund J, Heegaard S, Dacheva I, Koss M, Hu W, Iglesias B, Lawrence M, Beck H, Steffensen L, Laursen N, Andersen G, Holmskov U, Bates D, Sorensen G. Pharmacological blocking of microfibrillar-associated protein 4 reduces retinal neoangiogenesis and vascular leakage. Molecular Therapy 2025, 33: 1048-1072. PMID: 39863929, PMCID: PMC11897753, DOI: 10.1016/j.ymthe.2025.01.038.Peer-Reviewed Original ResearchConceptsMicrofibrillar-associated protein 4Vascular leakageNeovascular age-related macular degenerationAge-related macular degenerationChoroidal neovascularization mouse modelDiabetic macular edemaProtein 4Treatment of neovascularizationLaser-induced choroidal neovascularization mouse modelVascular leakage areaDuration of efficacyVascular endothelial cellsRetinal neoangiogenesisMacular edemaRetinal neovascularizationMacular degenerationVision lossRetinal diseasesPharmacological blockMuller cellsRetinal astrocytesVascular permeabilityVascular mural cellsEndothelial cell motilityMouse model
2024
Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema
Bressler S, Barve A, Ganapathi P, Beckmann K, Apte R, Marcus D, Baumane K, Agarwal S, Oleksy P, Reichstein D, Patel S, Ernest J, Dégi R, Gupta V, Kishino G, Kamei M, Loganathan S, Chaudhry N, Reichstein D, Tabassian A, Fine H, Sjaarda R, Marcus D, Barakat M, Dugel, P, Eichenbaum D, Dessouki A, Berger A, Angle B, Chang M, Patel S, Brown D, Thach A, Baker C, Gordon A, Mansour S, Fox G, Alfaro D, Davies J, Ghorayeb G, Stoller G, Johnson T, Nemcansky J, Rehak J, Studnicka J, Ernest J, Korda V, Veith M, Krzyzanek D, Kalvodova B, Stodulka P, Feltgen N, PD K, Grisanti S, Gamulescu M, Kellner U, Sekundo W, Dahlke C, Zeitz O, Baumane K, Laganovska G, Ozolina S, Vajas A, Seres A, Tsorbatzoglou A, Radnoti J, Kiss K, Gombos K, Degi R, Varsanyi B, Kerenyi A, Noge S, Muramatsu T, Kaga T, Oh H, Watanabe M, Oshima Y, Fujita H, Kishino G, Hanemoto T, Murata K, Kitaoka T, Saito I, Tanabe T, Ebihara N, Imaizumi H, Ishii K, Kamei M, Furuta M, Ojima A, Sawada O, Kawasaki T, Otake H, Doi N, Abe, K, Matsuda S, Kobayashi N, Yoshizumi Y, Budzinskaya M, Lebedev O, Eremina A, Zolotarev A, Izmaylov A, Samoylov A, Astakhov S, Astakhov Y, Shkvorchenko D, Narayanan R, Agarwal K, Rahul S, Natesh S, Gupta V, Panchal B, Kaza H, K M, Agrawal V, Elhence A, Behera U, Raj L, Mazumdar S, Kannan N, Yadav N, Vohra R, Aggarwal S, Sonawane A, Saravanan V, Chauhan R, Fluder E, Nawrocki J, Wylegala E, Zalewski D, Oleksy P, Borcz E. Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema. JAMA Ophthalmology 2024, 142: 952-960. PMID: 39264599, PMCID: PMC11393752, DOI: 10.1001/jamaophthalmol.2024.3458.Peer-Reviewed Original ResearchBest-corrected visual acuityDiabetic macular edemaCentral subfield thicknessEarly Treatment Diabetic Retinopathy StudyAflibercept groupAntidrug antibodiesAdverse eventsWeek 8Aflibercept armMacular edemaIncidence of treatment-emergent adverse eventsPrimary outcomeBaseline BCVA letter scoreTreatment Diabetic Retinopathy StudyTreatment-emergent adverse eventsIncidence of adverse eventsConsecutive intravitreal injectionsDiabetic Retinopathy StudyRandomized clinical trialsType 2 diabetesStudy eyesSubfield thicknessDouble-MaskedIntravitreal injectionRetinopathy Study
2021
Screening for obstructive sleep apnea in a diabetic retinopathy clinic in a tertiary care center
Kaswan R, Bansal R, Katoch D, Dogra M, Singh R, Gupta V, Dogra M, Bansal S. Screening for obstructive sleep apnea in a diabetic retinopathy clinic in a tertiary care center. Indian Journal Of Ophthalmology 2021, 69: 3349-3357. PMID: 34708803, PMCID: PMC8725143, DOI: 10.4103/ijo.ijo_3633_20.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaDiabetic macular edemaModerate-severe OSAApnea-hypopnea indexSevere DRDiabetic retinopathyEpworth Sleepiness ScaleSleep apneaStudies of obstructive sleep apneaObstructive sleep apnea riskTertiary care referral centerDetect obstructive sleep apneaDiabetic retinopathy clinicSTOP-Bang questionnaireSeverity of DRDepartment of OtorhinolaryngologyTertiary care centerOutcome measuresDiabetes mellitus patientsHypopnea indexRetina clinicCross-sectional studyMacular edemaSTOP-BangDR patients
2020
Refractive Error and Retinopathy Outcomes in Type 1 Diabetes The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
Hainsworth DP, Gao X, Bebu I, Das A, de Koo L, Barkmeier AJ, Tamborlane W, Lachin JM, Aiello LP, Group D. Refractive Error and Retinopathy Outcomes in Type 1 Diabetes The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Ophthalmology 2020, 128: 554-560. PMID: 32941962, PMCID: PMC7956062, DOI: 10.1016/j.ophtha.2020.09.014.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaDiabetic retinopathyRefractive errorProliferative DRMacular edemaDiabetes controlDiabetes InterventionsRisk factorsUnadjusted modelsComplications Trial/EpidemiologyStages of DRCox proportional hazards modelDCCT treatment groupEDIC years 4Refractive error statusStandard fundus photographsAlbumin excretion rateDuration of diabetesIndependent risk factorDCCT/EDICDiastolic blood pressureSignificant macular edemaProliferative diabetic retinopathyPotential risk factorsProportional hazards model
2018
Risk of Systemic Adverse Events Associated with Intravitreal Anti–VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice
Maloney MH, Schilz SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of Systemic Adverse Events Associated with Intravitreal Anti–VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice. Ophthalmology 2018, 126: 1007-1015. PMID: 30292542, DOI: 10.1016/j.ophtha.2018.09.040.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaRoutine clinical practiceSystemic serious adverse eventsMacular laserMajor bleedingCerebrovascular diseaseMyocardial infarctionClinical practiceCause hospitalizationAdverse eventsHazard ratioIntravitreal corticosteroidsAnti-VEGFMacular edemaDME treatmentTreatment of DMEIntravitreal anti-VEGF therapyCox proportional hazards regressionAnti-VEGF pharmacotherapySystemic safety profileCorticosteroid-treated patientsRetrospective cohort studySerious adverse eventsSystemic adverse eventsMacular laser photocoagulation
2017
Vitrectomy in the management of diabetic macular edema in treatment-naïve patients
Michalewska Z, Stewart MW, Landers MB, Bednarski M, Adelman RA, Nawrocki J. Vitrectomy in the management of diabetic macular edema in treatment-naïve patients. Canadian Journal Of Ophthalmology 2017, 53: 402-407. PMID: 30119796, DOI: 10.1016/j.jcjo.2017.10.011.Peer-Reviewed Original ResearchConceptsTreatment-naïve diabetic macular edemaDiabetic macular edemaCentral retinal thicknessPars plana vitrectomyMacular edemaVisual acuityPlana vitrectomyMean central retinal thicknessDuration of diabetesProspective randomized trialsTreatment-naïve patientsInitial visual acuityVisual acuity changesPrimary outcome measureEfficacy of vitrectomyElectronic medical recordsEarly vitrectomyIntravitreal bevacizumabFinal BCVAMean BCVAPrimary endpointRetinal thicknessConsecutive patientsRandomized trialsRetrospective study
2016
Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option
Ashraf M, Souka A, Adelman R, Forster SH. Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye 2016, 31: 342-345. PMID: 27813521, PMCID: PMC5306454, DOI: 10.1038/eye.2016.233.Peer-Reviewed Original ResearchAflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option
Ashraf M, Souka A, Adelman R, Forster SH. Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye 2016, 30: 1531-1541. PMID: 27564719, PMCID: PMC5177746, DOI: 10.1038/eye.2016.174.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaMacular edemaLarge phase 3 trialsBetter baseline VAEfficacy of afliberceptRole of afliberceptSecondary therapeutic optionsPhase 3 trialProtocol TBaseline VABimonthly regimenNata protocolAnatomic outcomesTherapeutic optionsPoor visionTreatment strategiesPrimary drugAfliberceptDifferent dosesDoseRanibizumabRegimenEdemaPatientsRecent dataPredicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature
Ashraf M, Souka A, Adelman R. Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature. British Journal Of Ophthalmology 2016, 100: 1596. PMID: 27231313, DOI: 10.1136/bjophthalmol-2016-308388.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaOptical coherence tomographyMacular edemaAnti-vascular endothelial growth factor therapyIntravitreal anti-vascular endothelial growth factorAnti-vascular endothelial growth factorEndothelial growth factor therapyFluorescein angiography findingsAnti-VEGF therapyAnti-VEGF agentsGrowth factor therapyCourse of treatmentCommon prognostic indicatorsEndothelial growth factorFactor therapyMost patientsVisual outcomeAngiography findingsChoroidal thicknessLarge RCTsTreatment regimenOCT parametersVisual acuityPrognostic indicatorDifferent RCTs
2015
Corrigendum to “Strategy for the Management of Diabetic Macular Edema: The European Vitreo‐Retinal Society Macular Edema Study”
Adelman RA, Parnes AJ, Michalewska Z, Parolini B, Boscher C, Ducournau D, Group E. Corrigendum to “Strategy for the Management of Diabetic Macular Edema: The European Vitreo‐Retinal Society Macular Edema Study”. BioMed Research International 2015, 2015: 694902. PMID: 26798639, PMCID: PMC4698543, DOI: 10.1155/2015/694902.Peer-Reviewed Original ResearchStrategy for the Management of Diabetic Macular Edema: The European Vitreo‐Retinal Society Macular Edema Study
Adelman R, Parnes A, Michalewska Z, Parolini B, Boscher C, Ducournau D. Strategy for the Management of Diabetic Macular Edema: The European Vitreo‐Retinal Society Macular Edema Study. BioMed Research International 2015, 2015: 352487. PMID: 25695062, PMCID: PMC4324105, DOI: 10.1155/2015/352487.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaMacular edemaVisual acuityVisual improvementBetter visual improvementMulticenter clinical studyPars plana vitrectomySignificant visual improvementEdema studyTriamcinolone monotherapyVEGF therapyVEGF injectionVision gainClinical findingsGrid laserPlana vitrectomyRetina specialistsClinical studiesDifferent therapiesClinical informationEdemaAcuityTherapyMean numberTreatment
2012
Ameliorative effect of PACAP and VIP against increased permeability in a model of outer blood retinal barrier dysfunction
Scuderi S, D’Amico A, Castorina A, Imbesi R, Carnazza M, D’Agata V. Ameliorative effect of PACAP and VIP against increased permeability in a model of outer blood retinal barrier dysfunction. Peptides 2012, 39: 119-124. PMID: 23220033, DOI: 10.1016/j.peptides.2012.11.015.Peer-Reviewed Original ResearchMeSH KeywordsBlood-Retinal BarrierCapillary PermeabilityCell LineClaudin-1DextransDiabetes ComplicationsElectric ImpedanceFluorescein-5-isothiocyanateGene ExpressionGlucoseHumansInterleukin-1betaMacular EdemaOccludinPituitary Adenylate Cyclase-Activating PolypeptideRetinal Pigment EpitheliumTight JunctionsVasoactive Intestinal PeptideZonula Occludens-1 ProteinConceptsDiabetic macular edemaBlood-retinal barrierTransepithelial electrical resistanceBRB functionBlood-retinal barrier dysfunctionOuter blood-retinal barrierEffects of PACAPHuman retinal pigment epithelial cellsFITC-dextran diffusionRetinal pigment epithelial cellsZO-1 expressionTight junctionsPigment epithelial cellsMacular edemaMajor complicationsInflammatory aspectsRetinal barrierRetinal injuryBarrier dysfunctionIL-1βDiabetic retinopathyDiabetic milieuTJ-related proteinsOccludin expressionNormal glucose
2009
An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema
V D, Nguyen QD, Shah SM, Browning DJ, Haller JA, Chu K, Yang K, Cedarbaum JM, Vitti RL, Ingerman A, Campochiaro PA. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. British Journal Of Ophthalmology 2009, 93: 144. PMID: 19174400, DOI: 10.1136/bjo.2008.138271.Peer-Reviewed Original ResearchConceptsVEGF Trap-EyeDiabetic macular edemaSingle intravitreal injectionVascular endothelial growth factor (VEGF) Trap-EyeExcess foveal thicknessFoveal thicknessIntravitreal injectionOptical coherence tomographyMacular edemaUnrelated serious adverse eventsMedian baseline BCVASerious adverse eventsBaseline BCVAETDRS lettersAdverse eventsRetinal thicknessVisual acuityOcular toxicityOutcome measuresBCVAMedian improvementPatientsCoherence tomographyAdditional studiesObservation period
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply